{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:28:15Z","timestamp":1793838495555,"version":"4.6.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10637-026-01623-1","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:22:16Z","timestamp":1781508136000},"page":"340-344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic hematopoietic stem cell transplantation with liposomal mitoxantrone conditioning for extramedullary leukemia"],"prefix":"10.1007","volume":"44","author":[{"given":"Lei","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixi","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuerong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0189-3392","authenticated-orcid":false,"given":"Fang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"issue":"4","key":"1623_CR1","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1016\/j.clml.2018.02.012","volume":"18","author":"AMS El-Ghammaz","year":"2018","unstructured":"El-Ghammaz AMS, El-Razzaz MK (2018) Risk factors influencing outcome of acute leukemia patients who experience relapse after allogeneic hematopoietic stem-cell transplantation. Clin Lymphoma Myeloma Leuk 18(4):e183\u2013e190. https:\/\/doi.org\/10.1016\/j.clml.2018.02.012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"1623_CR2","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.bbmt.2017.03.023","volume":"23","author":"N Shem-Tov","year":"2017","unstructured":"Shem-Tov N, Saraceni F, Danylesko Iea et al (2017) Isolated extramedullary relapse of acute leukemia after allogeneic stem cell transplantation: different kinetics and better prognosis than systemic relapse. Biol Blood Marrow Transplant 23(7):1087\u20131094. https:\/\/doi.org\/10.1016\/j.bbmt.2017.03.023","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"1623_CR3","doi-asserted-by":"publisher","first-page":"13343","DOI":"10.1021\/acsnano.0c05194","volume":"14","author":"KC Mei","year":"2020","unstructured":"Mei KC, Liao YP, Jiang Jea et al (2020) Liposomal delivery of mitoxantrone and a cholesteryl indoximod prodrug provides effective chemo-immunotherapy in multiple solid tumors. ACS Nano 14(10):13343\u201313366. https:\/\/doi.org\/10.1021\/acsnano.0c05194","journal-title":"ACS Nano"},{"issue":"2","key":"1623_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.22159\/ijap.2022v14i2.43474","volume":"14","author":"S Preethi","year":"2022","unstructured":"Preethi S, Kumar H, Rawal VB, Ajmeer R, Jain V (2022) Overview of mitoxantrone\u2014a potential candidate for treatment of breast cancer. Int J Appl Pharm 14(2):10\u201322. https:\/\/doi.org\/10.22159\/ijap.2022v14i2.43474","journal-title":"Int J Appl Pharm"},{"key":"1623_CR5","doi-asserted-by":"publisher","unstructured":"Gao Y, Huang Y, Zhang Qea, Zhang R, Zhang H, Zhang X, Huang H et al (2025) Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: a phase 2, multicenter, open-label, single-arm trial. Cancer 131(1):e35672. https:\/\/doi.org\/10.1002\/cncr.35672","DOI":"10.1002\/cncr.35672"},{"key":"1623_CR6","doi-asserted-by":"publisher","unstructured":"Gogoi M, Kumar N, Patra S (2016) Multifunctional magnetic liposomes for cancer imaging and therapeutic applications, in: Nanoarchitectonics for smart delivery and drug targeting. pp 743\u2013782.\u00a0https:\/\/doi.org\/10.1016\/B978-0-323-47347","DOI":"10.1016\/B978-0-323-47347"},{"key":"1623_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.addr.2013.11.004","volume":"66","author":"S Biswas","year":"2014","unstructured":"Biswas S, Torchilin VP (2014) Nanopreparations for organelle-specific delivery in cancer. Adv Drug Deliv Rev 66:26\u201341. https:\/\/doi.org\/10.1016\/j.addr.2013.11.004","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"1623_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/med.21364","volume":"36","author":"BJ Evison","year":"2016","unstructured":"Evison BJ, Sleebs BE, Watson KG, Phillips DR, Cutts SM (2016) Mitoxantrone, more than just another topoisomerase II poison. Med Res Rev 36(2):248\u2013299. https:\/\/doi.org\/10.1002\/med.21364","journal-title":"Med Res Rev"},{"issue":"1","key":"1623_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bbmt.2018.07.021","volume":"25","author":"R Zhang","year":"2019","unstructured":"Zhang R, Lu X, Wang H, Zhang Cea et al (2019) Idarubicin-intensified hematopoietic cell transplantation improves relapse and survival of high-risk acute leukemia patients with minimal residual disease. Biol Blood Marrow Transplant 25(1):47\u201355. https:\/\/doi.org\/10.1016\/j.bbmt.2018.07.021","journal-title":"Biol Blood Marrow Transplant"},{"key":"1623_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.leukres.2017.06.012","volume":"46","author":"J Fang","year":"2019","unstructured":"Fang J, Zhang R, Wang H et al (2019) Corrigendum to \u2019Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective comparative study.\u2019 [Leuk Res. 2016 Jul;46:61-68.]. Leuk Res 46:61\u201368. https:\/\/doi.org\/10.1016\/j.leukres.2017.06.012","journal-title":"Leuk Res"},{"issue":"4","key":"1623_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70116","volume":"43","author":"X Zhang","year":"2025","unstructured":"Zhang X, Yang D, Pang Aea et al (2025) The efficacy and safety of the addition of mitoxantrone hydrochloride liposome in conditioning regimen for high-risk acute myeloid leukemia. Hematol Oncol 43(4):e70116. https:\/\/doi.org\/10.1002\/hon.70116","journal-title":"Hematol Oncol"},{"issue":"3","key":"1623_CR12","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/ajh.26800","volume":"98","author":"H Liu","year":"2023","unstructured":"Liu H, Huang F, Zhang Y, Liu X, Liu Q et al (2023) Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: an open-label, multicenter, randomized phase 3 trial. Am J Hematol 98(3):408\u2013412","journal-title":"Am J Hematol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01623-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01623-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01623-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:05:51Z","timestamp":1793837151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01623-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1623"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01623-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"3 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee of the 960th Hospital of the People\u2019s Liberation Army (2024\u2013132).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants agreed to provide their basic and treatment information and consented to publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We confirm that no organs or tissues were procured from prisoners for this study. Hematopoietic stem cells were obtained from the China Marrow Donor Program or patients\u2019 relatives.","order":4,"name":"Ethics","label":"Hematopoietic stem cell source statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}